Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Carnival Corp (CCL) Price & Performance

Alnylam Pharmaceuticals, Inc.Trade
Carnival CorpTrade

Price performance (Past 24H)

Key statistics

Alnylam Pharmaceuticals, Inc. vs Carnival Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while Carnival Corp trades at $27.72 (market cap $37.98B). The key difference: Carnival Corp is the larger of the two by market cap, and Carnival Corp pays a 1.62% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.

ALNYCCL
Market Cap
$29.60B$37.98B
Sector
HealthConsumer Cyclical
52-Week High
$491.22$33.99
52-Week Low
$205.48$23.89
Enterprise Value
$27.56B$61.91B
Dividend Yield
1.62%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alnylam Pharmaceuticals, Inc.

ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.

The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.

Carnival Corp

Carnival Corporation (CCL) trades at $27.77, showing minimal daily movement with a 0.07% gain. The stock demonstrates strong fundamental recovery with revenue growing from $12.2B in 2022 to $26.6B in 2025, while net income turned positive at $2.76B. Technical indicators show bearish momentum despite neutral oscillators, with key support at $27 and resistance at $28. Recent corporate developments include new voyage bookings through 2029 and continued dividend payments of $0.15 per share.

CCL presents a compelling recovery story with improving profitability and debt reduction, though near-term technical weakness and fuel cost risks persist. Analyst consensus remains bullish with a $35.18 price target representing 27% upside potential. The stock offers exposure to the rebounding cruise industry but faces sensitivity to economic conditions and operational execution challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

Read more on ALNY

About Carnival Corp

Carnival is the largest global cruise company, with 91 ships in its fleet in October 2022, with eight of its nine brands set to be fully redeployed by the end of 2022. Its portfolio of brands includes Carnival Cruise Lines, Holland America, Princess Cruises, and Seabourn in North America.

Read more on CCL